SLXN · Silexion Therapeutics Corp · Share Buybacks
$0.26
0.00 (-1.89%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our consolidated financial statements for the three-month and six-month periods ended June 30, 2026 included in this quarterly report, but rather, under our current business plan, through the fourth quarter of 2026 and, as a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.45M
Shares
5.56M
Volume · Oct 5
1.23M
Avg daily vol (3M)
9.82M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
59,525 shares
as of 2024-07-04
· not restated in filings since 2025-05-13
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-09-26 | — | $13,170,000 | $10,900,000 as of 2026-08-14 | — | 10-Q , filed 2026-08-14 |